Micah Mackison
Directeur Général chez Vico Therapeutics BV
Profil
Micah Mackison is the founder of Nexhand, Inc. founded in 2011.
Currently, he is the Chief Executive Officer at Vico Therapeutics BV since 2022 and also holds a position as Director at Scioto Biosciences, Inc. Mr. Mackison's former positions include Senior Director-Corporate Investment Life Sciences at Jabil, Inc., Senior Director-New Ventures at H.
Lundbeck A, Director-Corporate Development at OVATION Pharmaceuticals, Inc., Managing Director at Oakridge Bioventures LLC, and SVP-Corporate Development & Strategy at Assembly Biosciences, Inc. Mr. Mackison completed his undergraduate degree at Indiana University.
Postes actifs de Micah Mackison
| Sociétés | Poste | Début |
|---|---|---|
Scioto Biosciences, Inc.
 Scioto Biosciences, Inc. BiotechnologyHealth Technology Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN. | Directeur/Membre du Conseil | - |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Directeur Général | 01/08/2022 |
Anciens postes connus de Micah Mackison
| Sociétés | Poste | Fin |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 01/04/2020 |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 01/01/2009 |
| H. LUNDBECK A/S | Corporate Officer/Principal | - |
| JABIL INC. | Corporate Officer/Principal | - |
| Nexhand, Inc. | Fondateur | - |
Formation de Micah Mackison
| Indiana University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| JABIL INC. | Electronic Technology |
| H. LUNDBECK A/S | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
| Nexhand, Inc. | Health Technology |
| Oakridge Bioventures LLC | |
Scioto Biosciences, Inc.
Scioto Biosciences, Inc. BiotechnologyHealth Technology Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN. | Health Technology |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
